Skip to main content
Clinical Trials/NCT00291317
NCT00291317CompletedNot Applicable

The Effect of FES on Children With Spinal Cord Dysfunction

Children's Specialized Hospital0 sites6 target enrollmentStarted: January 1, 2006Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
6
Primary Endpoint
Change in Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0)Score.

Study Overview

Brief Summary

Regular exercise is strongly recommended to help maintain a healthy lifestyle. Unfortunately, children and young adults with damaged spinal cords may not be able to exercise regularly. However, there is an exercise bike specially designed for persons with damaged spinal cords that enables them to pedal by directly stimulating the muscles in their legs. Our study is designed to determine the benefits of exercise for Spinal Cord Injured (SCI) patients using this bike.

Detailed Description

The inability to walk due to spinal cord dysfunction has profound effects on patients, both physiologically and psychologically. Complications associated with walking upright include loss of muscle mass from atrophy, reduction in bone mineral density (osteoporosis), compromised cardiovascular endurance, loss of sense of well-being, etc. Functional Electrical Stimulation (FES) of the lower extremities has been found to reverse many of these complications. We propose to examine the use of FES in children who have suffered from spinal cord injury (SCI). We plan to examine the effect of FES bike therapy on bone mineral density and psychological well-being.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
4 Years to 21 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Paralysis/lack of sensation in lower extremities due to spinal cord injury.

Exclusion Criteria

  • Diseases known to affect bone metabolism
  • A history of hip or knee dislocation or subluxation
  • The presence of pressure sores in the areas of treatment
  • The presence of metallic hardware in the femur
  • A history of peripheral nerve injury, lower motor neuron disease, or chronic corticosteroid use; or a seizure disorder requiring pharmacological antiepileptic therapy that can affect bone mineral density.
  • Individuals with pacemaker devices or unhealed fractures also were excluded.

Outcomes

Primary Outcomes

Change in Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0)Score.

Time Frame: pre- and post-intervention; time frame among participants ranged from 4 to 12 months

The PedsQL™ 4.0 is a modular instrument for measuring health-related quality of life in children and adolescents. The questionnaire asks how much of a problem each item has been during the past month, using a 5-point response scale. This study used the Emotional Functioning, Social Functioning, and School Functioning modules. Scores on these three modules are combined to yield a Psychosocial Health Summary Score (range = 0-100 with 100 being the maximum positive outcome). Pre- and post-intervention scores were compared to determine improvement.

Change in Bone Mineral Density Measured Via DEXA Scan

Time Frame: At entry until completion (range 4-14 months) (One participant's DEXA scan was obtained late due to illness)

Bone mineral density (BMD) was measured with Dual X-ray Absorptiometry (DEXA) scans using a GE LUNAR system. DEXA has been used in patients with loss of ambulation due to SCI to monitor changes in body composition over time and to evaluate the effectiveness of exercise in preventing or reducing the disease-related complications of SCI. It was used in the present study to determine BMD in the right distal femur at baseline; after 3 months of intervention; after 6 months; and for children who biked for the full duration of the study, at the completion of 9 months of intervention.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Children's Specialized Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. Frank Castello

Medical Director

Children's Specialized Hospital

Similar Trials